UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 4, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware13-5315170

(State of Incorporation)(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

Common Stock, $.05 par valuePFENew York Stock Exchange

0.250% Notes due 2022PFE22New York Stock Exchange

1.000% Notes due 2027PFE27New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YesxNo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

YesxNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes Nox

At May 10, 2021, 5,597,693,867 shares of the issuer s voting common stock were outstanding.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income

Condensed Consolidated Statements of Comprehensive Income

Condensed Consolidated Balance Sheets7

Condensed Consolidated Statements of Equity

Condensed Consolidated Statements of Cash Flows

Notes to Condensed Consolidated Financial Statements

10

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

34

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

51

Item 4.

Controls and Procedures

51

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

52

Item 1A.

Risk Factors

52

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

52

Item 3.

Defaults Upon Senior SecuritiesN/A

Item 4.

Mine Safety DisclosuresN/A

Item 5.

Other InformationN/A

Item 6.

Exhibits

52

Signature

53

N/A = Not Applicable

DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. References to Notes in this Form 10-Q are to the notes to the condensed or consolidated financial statements in this Form 10-Q or our 2020 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined:

2020 Form 10-KAnnual Report on Form 10-K for the fiscal year ended December 31, 2020

ACIPAdvisory Committee on Immunization Practices

ALKanaplastic lymphoma kinase

Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

AllogeneAllogene Therapeutics, Inc.

AMLAcute Myeloid Leukemia

ArrayArray BioPharma Inc.

AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

ATTR-CMtransthyretin amyloid cardiomyopathy

BioNTechBioNTech SE

BLABiologics License Application

BMSBristol-Myers Squibb Company

BNT162b2Pfizer-BioNTech COVID-19 Vaccine

BODBoard of Directors

CDCU.S. Centers for Disease Control and Prevention

CMAconditional marketing authorization

Consumer Healthcare JVGSK Consumer Healthcare JV

COVID-19novel coronavirus disease of 2019

Developed EuropeIncludes the following markets: Western Europe, Scandinavian countries and Finland

Developed MarketsIncludes the following markets: U.S., Developed Europe, Japan, Canada, Australia, South Korea and New Zealand

Developed Rest of WorldIncludes the following markets: Japan, Canada, Australia, South Korea and New Zealand

EMAEuropean Medicines Agency

Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Eastern Europe, Latin America, Central Europe, the Middle East, Africa and Turkey

EPSearnings per share

EUEuropean Union

EUAemergency use authorization

Exchange ActSecurities Exchange Act of 1934, as amended

FDAU.S. Food and Drug Administration

Form 10-QQuarterly Report on Form 10-Q for the quarterly period ended April 4, 2021

GAAPGenerally Accepted Accounting Principles

GISTgastrointestinal stromal tumors

GSKGlaxoSmithKline plc

HospiraHospira, Inc.

IPR&Din-process research and development

IRSU.S. Internal Revenue Service

JVjoint venture

KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)

LIBORLondon Interbank Offered Rate

LillyEli Lilly & Company

LOEloss of exclusivity

MCOmanaged care organization

mCRCmetastatic colorectal cancer

mCRPCmetastatic castration-resistant prostate cancer

mCSPCmetastatic castration-sensitive prostate cancer

MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations

MeridianMeridian Medical Technologies, Inc.

MTMmark-to-market

MylanMylan N.V.

Mylan-Japan collaborationa pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan that terminated on December 21, 2020

MyovantMyovant Sciences Ltd.

nmCRPCnon-metastatic castration-resistant prostate cancer

NSCLCnon-small cell lung cancer

OPKOOPKO Health, Inc.

OTCover-the-counter

PBMpharmacy benefit manager

PGSPfizer Global Supply

PharmaciaPharmacia Corporation

PsApsoriatic arthritis

RArheumatoid arthritis

RCCrenal cell carcinoma

R&Dresearch and development

SandozSandoz, Inc., a division of Novartis AG

SECU.S. Securities and Exchange Commission

SI&Aselling, informational and administrative

UCulcerative colitis

U.K.United Kingdom

U.S.United States

Upjohn BusinessPfizer s global, primarily off-patent branded and generics business, which includes a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris

ViatrisViatris Inc.

This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.

Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.

The information contained on our website, our Facebook, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)April 4,

2021March 29,

2020

Revenues$14,582 $10,083

Costs and expenses:

Cost of sales(a)

4,211 1,940

Selling, informational and administrative expenses(a)

2,783 2,541

Research and development expenses(a)

2,014 1,672

Amortization of intangible assets872 849

Restructuring charges and certain acquisition-related costs

23 54

(Gain) on completion of Consumer Healthcare JV transaction

(6)

Other (income)/deductions net

(1,004)190

Income from continuing operations before provision for taxes on income5,683 2,842

Provision for taxes on income805 359

Income from continuing operations4,877 2,483

Income from discontinued operations net of tax9 881

Net income before allocation to noncontrolling interests4,886 3,364

Less: Net income attributable to noncontrolling interests9 9

Net income attributable to Pfizer Inc. common shareholders$4,877 $3,355

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders$0.87 $0.45

Income from discontinued operations net of tax 0.16

Net income attributable to Pfizer Inc. common shareholders$0.87 $0.60

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders$0.86 $0.44

Income from discontinued operations net of tax 0.16

Net income attributable to Pfizer Inc. common shareholders$0.86 $0.60

Weighted-average shares basic5,584 5,545

Weighted-average shares diluted5,662 5,613

(a)Exclusive of amortization of intangible assets, except as disclosed in Note 9 in this Form 10-Q and Note 1L in our 2020 Form 10-K.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

(MILLIONS)April 4,

2021March 29,

2020

Net income before allocation to noncontrolling interests$4,886 $3,364

Foreign currency translation adjustments, net465 (1,256)

Unrealized holding gains/(losses) on derivative financial instruments, net214 (501)

Reclassification adjustments for (gains)/losses included in net income(a)

259 19

473 (482)

Unrealized holding gains/(losses) on available-for-sale securities, net79 (51)

Reclassification adjustments for (gains)/losses included in net income(b)

(242)15

(163)(36)

Reclassification adjustments related to amortization of prior service costs and other, net(40)(45)

Other(3)(1)

(43)(45)

Other comprehensive income/(loss), before tax732 (1,821)

Tax provision/(benefit) on other comprehensive income/(loss)84 (380)

Other comprehensive income/(loss) before allocation to noncontrolling interests$647 $(1,441)

Comprehensive income/(loss) before allocation to noncontrolling interests$5,533 $1,923

Less: Comprehensive income/(loss) attributable to noncontrolling interests10 9

Comprehensive income/(loss) attributable to Pfizer Inc.$5,523 $1,914

(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.

(b)Reclassified into Other (income)/deductions net.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS)April 4,

2021December 31, 2020

(Unaudited)

Assets

Cash and cash equivalents$1,768 $1,784

Short-term investments11,899 10,437

Trade accounts receivable, less allowance for doubtful accounts: 2021 $512; 2020 $508

9,864 7,930

Inventories8,493 8,046

Current tax assets3,419 3,264

Other current assets4,091 3,605

Total current assets39,533 35,067

Equity-method investments16,532 16,856

Long-term investments3,696 3,406

Property, plant and equipment, less accumulated depreciation: 2021 $15,105; 2020 $14,812

14,011 13,900

Identifiable intangible assets27,974 28,471

Goodwill49,791 49,577

Noncurrent deferred tax assets and other noncurrent tax assets2,537 2,383

Other noncurrent assets4,744 4,569

Total assets$158,818 $154,229

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2021 $3,676; 2020 $2,002

$4,352 $2,703

Trade accounts payable4,064 4,309

Dividends payable 2,162

Income taxes payable1,401 1,049

Accrued compensation and related items1,985 3,058

Deferred revenues2,052 1,113

Other current liabilities12,798 11,527

Total current liabilities26,652 25,920

Long-term debt35,347 37,133

Pension benefit obligations4,526 4,766

Postretirement benefit obligations635 645

Noncurrent deferred tax liabilities4,355 4,063

Other taxes payable11,759 11,560

Other noncurrent liabilities6,677 6,669

Total liabilities89,953 90,756

Commitments and Contingencies

Common stock472 470

Additional paid-in capital89,002 88,674

Treasury stock(111,349)(110,988)

Retained earnings95,158 90,392

Accumulated other comprehensive loss(4,664)(5,310)

Total Pfizer Inc. shareholders equity68,620 63,238

Equity attributable to noncontrolling interests245 235

Total equity68,865 63,473

Total liabilities and equity$158,818 $154,229

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)

PFIZER INC. SHAREHOLDERS

Preferred StockCommon StockTreasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)

SharesStated ValueSharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 2021 $ 9,407 $470 $88,674 (3,840)$(110,988)$90,392 $(5,310)$63,238 $235 $63,473

Net income4,877 4,877 9 4,886

Other comprehensive income/(loss), net of tax

646 646 1 647

Cash dividends declared, per share: $

Common stock

(84)(84)(84)

Preferred stock

Noncontrolling interests

Share-based payment transactions

38 2 329 (11)(361)(30)(30)

Purchases of common stock

Preferred stock conversions and redemptions

Other (27)(27) (27)

Balance, April 4, 2021 $ 9,445 $472 $89,002 (3,851)$(111,349)$95,158 $(4,664)$68,620 $245 $68,865

PFIZER INC. SHAREHOLDERS

Preferred StockCommon StockTreasury Stock

(MILLIONS, EXCEPT PREFERRED SHARES)

SharesStated ValueSharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 2020431 $17 9,369 $468 $87,428 (3,835)$(110,801)$91,397 $(5,367)$63,143 $303 $63,447

Net income3,355 3,355 9 3,364

Other comprehensive income/(loss), net of tax

(1,441)(1,441) (1,441)

Cash dividends declared, per share: $

Common stock

(71)(71)(71)

Preferred stock

Noncontrolling interests

Share-based payment transactions

23 1 252 (6)(209)44 44

Purchases of common stock

Preferred stock conversions and redemptions

(14)(1)(1) (1)(1)

Other

Balance, March 29, 2020417 $17 9,393 $470 $87,680 (3,841)$(111,010)$94,680 $(6,808)$65,028 $312 $65,341

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Three Months Ended

(MILLIONS)April 4,

2021March 29,

2020

Operating Activities

Net income before allocation to noncontrolling interests$4,886 $3,364

Income from discontinued operations net of tax9 881

Net income from continuing operations before allocation to noncontrolling interests4,877 2,483

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:

Depreciation and amortization1,226 1,166

Asset write-offs and impairments46 44

Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed (6)

Deferred taxes from continuing operations199 82

Share-based compensation expense172 57

Benefit plan contributions in excess of expense/income(373)(276)

Other adjustments, net(291)120

Other changes in assets and liabilities, net of acquisitions and divestitures(1,327)(1,515)

Net cash provided by operating activities from continuing operations4,530 2,155

Net cash provided by operating activities from discontinued operations9 978

Net cash provided by operating activities4,538 3,133

Investing Activities

Purchases of property, plant and equipment(554)(449)

Purchases of short-term investments(6,054)(2,551)

Proceeds from redemptions/sales of short-term investments5,465 3,257

Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less(996)(416)

Purchases of long-term investments(27)(22)

Proceeds from redemptions/sales of long-term investments256 152

Other investing activities, net163 (24)

Net cash provided by/(used in) investing activities from continuing operations(1,747)(53)

Net cash provided by/(used in) investing activities from discontinued operations (19)

Net cash provided by/(used in) investing activities(1,747)(71)

Financing Activities

Proceeds from short-term borrowings 5,302

Principal payments on short-term borrowings (7,551)

Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less

(25)3,207

Proceeds from issuance of long-term debt 1,241

Principal payments on long-term debt (2,181)

Cash dividends paid(2,172)(2,105)

Other financing activities, net(610)(113)

Net cash provided by/(used in) financing activities from continuing operations(2,807)(2,200)

Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents

(15)

Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents(15)846

Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period1,825 1,350

Cash and cash equivalents and restricted cash and cash equivalents, at end of period$1,809 $2,196

Supplemental Cash Flow Information

Cash paid (received) during the period for:

Income taxes

$394 $239

Interest paid

445 472

Interest rate hedges

10 (11)

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2020 Form 10-K, except as disclosed in Note 1C. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.

These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2020 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three months ended February 28, 2021 and February 23, 2020, and for U.S. subsidiaries is as of and for the three months ended April 4, 2021 and March 29, 2020.

Business development activities impacted financial results in the periods presented. See Note 1A in our 2020 Form 10-K, and Note 2. On November 16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. For additional information, see Note 2B in our 2020 Form 10-K. On December 21, 2020, which falls in Pfizer s international first quarter of 2021, Pfizer and Viatris completed the termination of the Mylan-Japan collaboration pursuant to an agreement dated November 13, 2020 and we transferred related inventories and operations that were part of the Mylan-Japan collaboration to Viatris. As a result, the financial position and results of operations of the Upjohn Business and the Mylan-Japan collaboration are presented as discontinued operations for all periods presented. Prior-period information has been restated to reflect our current organization structure.

B. New Accounting Standard Adopted in 2021

On January 1, 2021, we adopted a new accounting standard for income tax that eliminates certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The adoption of this guidance did not have a material impact on our condensed consolidated financial statements.

For information on new accounting standards adopted in 2020, see Note 1B in our 2020 Form 10-K.

C. Change in Accounting Principle

In the first quarter of 2021, we adopted a change in accounting principle to a more preferable policy under U.S. GAAP to immediately recognize actuarial gains and losses arising from the remeasurement of our pension and postretirement plans ( MTM Accounting ). Under the prior policy, we deferred recognition of these gains and losses in Accumulated other comprehensive loss. The accumulated actuarial gains/losses outside of a corridor were then amortized into net periodic benefit costs over the average remaining service period or the average life expectancy of participants. This change has been applied to all pension and postretirement plans on a retrospective basis for all prior periods presented, and as of January 1, 2020, resulted in a cumulative effect decrease to Retained earnings of $6.3 billion, with a corresponding offset to Accumulated other comprehensive loss. Each time a pension or postretirement plan is remeasured, the actuarial gain or loss is recognized immediately and classified as Other (income)/deductions net.

We believe that MTM Accounting is a more preferable policy as it provides improved transparency of results and performance, better alignment with fair value accounting principles and a better reflection of current economic and interest rate trends on plan investments and assumptions and the actuarial impact of plan remeasurements.

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The impacts of the adjustments on our condensed consolidated financial statements are summarized as follows:

Three Months Ended

April 4, 2021

March 29, 2020

(MILLIONS, EXCEPT PER COMMON SHARE DATA)Previous Accounting Principle

Impact of ChangeAs ReportedPrevious Accounting PrincipleImpact of ChangeAs Adjusted

Condensed Consolidated Statements of Income:

Other (income)/deductions net$(857)$(146)$(1,004)$216 $(25)$190

Income from continuing operations before provision for taxes on income5,536 146 5,683 2,817 25 2,842

Provision for taxes on income773 32 805 355 4 359

Income from discontinued operations net of tax9 9 948 (68)881

Net income before allocation to noncontrolling interests4,772 114 4,886 3,410 (47)3,364

Net income attributable to Pfizer Inc. common shareholders4,763 114 4,877 3,401 (47)3,355

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders$0.85 $0.02 $0.87 $0.44 $ $0.45

Income from discontinued operations net of tax 0.17 (0.01)0.16

Net income attributable to Pfizer Inc. common shareholders0.85 0.02 0.87 0.61 (0.01)0.60

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders$0.84 $0.02 $0.86 $0.44 $ $0.44

Income from discontinued operations net of tax 0.17 (0.01)0.16

Net income attributable to Pfizer Inc. common shareholders0.84 0.02 0.86 0.61 (0.01)0.60

Condensed Consolidated Statements of Comprehensive Income:

Foreign currency translation adjustments, net$546 $(81)$465 $(1,272)$16 $(1,256)

Benefit plans: actuarial gains/(losses), net47 (47) (166)166

Reclassification adjustments related to amortization75 (75) 66 (66)

Reclassification adjustments related to settlements, net19 (19) 53 (53)

Other(81)81 16 (16)

Tax provision/(benefit) on other comprehensive income/(loss)72 12 84 (377)(3)(380)

Condensed Consolidated Statements of Cash Flows:

Deferred taxes from continuing operations$167 $32 $199 $77 $4 $82

Benefit plan contributions in excess of expense/income(226)(146)(373)(250)(25)(276)

April 4, 2021

December 31, 2020

(MILLIONS)Previous Accounting Principle

Impact of ChangeAs ReportedPrevious Accounting PrincipleImpact of ChangeAs Adjusted

Condensed Consolidated Balance Sheets:

Noncurrent deferred tax assets and other noncurrent tax assets$2,569 $(32)$2,537 $2,383 $ $2,383

Other noncurrent assets4,738 6 4,744 4,569 4,569

Pension benefit obligations4,527 4,526 4,766 4,766

Retained earnings95,044 114 95,158 96,770 (6,378)90,392

Accumulated other comprehensive loss(4,523)(141)(4,664)(11,688)6,378 (5,310)

D. Revenues and Trade Accounts Receivable

Customers Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. In the U.S., we primarily sell our vaccines products directly to the federal government, CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.

11

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:

(MILLIONS)April 4,

2021December 31, 2020

Reserve against Trade accounts receivable, less allowance for doubtful accounts

$848 $861

Other current liabilities:

Accrued rebates3,211 3,017

Other accruals449 436

Other noncurrent liabilities

340 399

Total accrued rebates and other sales-related accruals$4,848 $4,712

Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.

In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. These credit risk indicators are monitored on a quarterly basis to determine whether there have been any changes in the economic environment that would indicate the established reserve percentages should be adjusted, and are considered on a regional basis to reflect more geographic-specific metrics. Additionally, write-offs and recoveries of customer receivables are tracked against collections on a quarterly basis to determine whether the reserve percentages remain appropriate. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.

During the three months ended April 4, 2021 and March 29, 2020, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see Note 1G in our 2020 Form 10-K.

Note 2. Discontinued Operations and Equity-Method Investment

A. Discontinued Operations

Upjohn Separation and Combination with Mylan

On November 16, 2020, we completed the spin-off and the combination of the Upjohn Business with Mylan to form Viatris. See Note 1A.

In connection with this transaction, Pfizer and Viatris entered into various agreements to effect the separation and combination to provide a framework for our relationship after the combination, including a separation and distribution agreement, interim operating models, including agency arrangements, manufacturing and supply agreements (MSAs), transition service agreements (TSAs), a tax matters agreement, and an employee matters agreement, among others. The interim agency operating model arrangements primarily include billings, collections and remittance of rebates that we are performing on a transitional basis on behalf of Viatris. Under the MSAs, Pfizer or Viatris, as the case may be, manufactures, labels and packages products for the other party. In the first three months of 2021, the amounts recorded under the above agreements were not material to our consolidated results of operations. Net amounts due from Viatris under the above agreements were approximately $871 million as of April 4, 2021 and $401 million as of December 31, 2020. The cash flows associated with the above agreements are included in Net cash provided by operating activities from continuing operations, except for a $277 million payment to Viatris made in the first quarter of 2021 pursuant to terms of the separation agreement, which is reported in Other financing activities, net, and was recorded as a payable to Viatris in Other current liabilities as of December 31, 2020. In addition, Pfizer and Mylan had pre-existing arms-length commercial agreements, which are continuing with Viatris and are not material to Pfizer s consolidated financial statements.

The operating results of the Upjohn Business and the Mylan-Japan collaboration are reported as Income from discontinued operations net of tax.

12

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Components of Income from discontinued operations net of tax:

Three Months Ended(a)

(MILLIONS)April 4,

2021March 29,

2020

Revenues$27 $1,946

Costs and expenses:

Cost of sales14 442

Selling, informational and administrative expenses(8)332

Research and development expenses1 51

Amortization of intangible assets 36

Restructuring charges and certain acquisition-related costs 15

Other (income)/deductions net1 70

Pre-tax income from discontinued operations19 1,000

Provision for taxes on income10 119

Income from discontinued operations net of tax$9 $881

(a)In the three months ended April 4, 2021, Income from discontinued operations net of tax primarily relates to the Mylan-Japan collaboration, which did not terminate until December 21, 2020 and which falls in Pfizer s international first quarter of 2021, and adjustments to tax and legal matters directly related to the disposed Upjohn Business. In the three months ended March 29, 2020, Income from discontinued operations net of tax relates to the Upjohn Business and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting, which has been applied on a retrospective basis for all prior periods presented. See Note 1C.

B. Equity-Method Investment

Formation of Consumer Healthcare JV

On July 31, 2019, we completed a transaction in which we and GSK combined our respective consumer healthcare businesses into a new JV that operates globally under the GSK Consumer Healthcare name. In exchange, we received a 32% equity stake in the new company and GSK owns the remaining 68%.

We are accounting for our interest in the Consumer Healthcare JV as an equity-method investment. The carrying value of our investment in the Consumer Healthcare JV is $16.3 billion as of April 4, 2021 and $16.7 billion as of December 31, 2020 and is reported as a private equity investment in Equity-method investments as of April 4, 2021 and December 31, 2020. The Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The decrease in the value of our investment from December 31, 2020 is primarily due to $126 million in pre-tax foreign currency translation adjustments (see Note 6), as well as dividends totaling approximately $274 million, partially offset by our share of the JV s earnings. We record our share of earnings from the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in Other (income)/deductions net. Our total share of the JV s earnings generated in the fourth quarter of 2020, which we recorded in our operating results in the first quarter of 2021, was $71 million. Our total share of the JV s earnings generated in the fourth quarter of 2019, which we recorded in our operating results in the first quarter of 2020 was $11 million. See Note 4. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the JV is included in Other (income)/deductions net and was not material to our results of operations in the periods presented. See Note 4.

Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three months ending December 31, 2020, the most recent period available and for the three months ending December 31, 2019, is as follows:

Three Months Ended

(MILLIONS)December 31, 2020December 31, 2019

Net sales$3,096 $3,188

Cost of sales(1,188)(1,811)

Gross profit$1,908 $1,377

Income from continuing operations233 46

Net income233 46

Income attributable to shareholders221 37

13

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

A. Transforming to a More Focused Company Program

With the formation of the Consumer Healthcare JV in 2019 and the spin-off of our Upjohn Business in the fourth quarter of 2020, Pfizer has transformed into a focused, global leader in science-based innovative medicines and vaccines. We have undertaken efforts to ensure our cost base aligns appropriately with our revenue base. While certain direct costs transferred to the Consumer Healthcare JV and to the Upjohn Business in connection with the spin-off, there are indirect costs which did not transfer. In addition, we are taking steps to restructure our corporate enabling functions to appropriately support and drive the purpose of our business and R&D and PGS platform functions. The program costs discussed below are expected to be incurred primarily from 2020 through 2022, and may be rounded and represent approximations.

We expect costs for this program, primarily related to corporate enabling functions, to total $1.6 billion on a pre-tax basis, with substantially all costs to be cash expenditures. Actions will include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs will primarily include severance and benefit plan impacts, exit costs as well as associated implementation costs.

Also, as part of this program, we expect to incur costs related to manufacturing network optimization, including certain legacy cost-reduction initiatives, of $500 million, with approximately 20% of the costs to be non-cash. The costs for this effort will include, among other things, implementation costs, product transfer costs, site exit costs, as well as accelerated depreciation.

From the start of this program in the fourth quarter of 2019 through April 4, 2021, we incurred costs of $1.0 billion.

B. Key Activities

The following summarizes acquisitions and cost-reduction/productivity initiatives costs and credits, which are composed primarily of the Transforming to a More Focused Company program:

Three Months Ended

(MILLIONS)April 4,

2021March 29,

2020

Restructuring charges/(credits):

Employee terminations

$22 $10

Asset impairments

(4)31

Restructuring charges/(credits)(a)

18 41

Transaction costs(b)

Integration costs and other(c)

5 10

Restructuring charges and certain acquisition-related costs

23 54

Net periodic benefit costs recorded in Other (income)/deductions net(d)

8 1

Additional depreciation asset restructuring recorded in our condensed consolidated statements of income as follows(e):

Cost of sales

10 5

Research and development expenses

(5)

Total additional depreciation asset restructuring

10

Implementation costs recorded in our condensed consolidated statements of income as follows(f):

Cost of sales

11 8

Selling, informational and administrative expenses

64 15

Total implementation costs

75 22

Total costs associated with acquisitions and cost-reduction/productivity initiatives

$116 $77

(a)Represents acquisition-related costs ($6 million credit in 2021) and cost-reduction/productivity initiatives ($25 million charge in 2021 and a $40 million charge in 2020).

(b)Represents external costs for banking, legal, accounting and other similar services.

(c)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.

(d)Amount for the three months ended March 29, 2020 includes the impact of a change in accounting principle. See Note 1C.

(e)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(f)Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

14

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following summarizes the components and changes in restructuring accruals:

(MILLIONS)Employee

Termination

CostsAsset

Impairment

ChargesExit CostsAccrual

Balance, December 31, 2020(a)

$782 $ $15 $798

Provision22 (4) 18

Utilization and other(b)

(102)4 (99)

Balance, April 4, 2021(c)

$702 $ $15 $717

(a)Included in Other current liabilities ($628 million) and Other noncurrent liabilities ($169 million).

(b)Includes adjustments for foreign currency translation.

(c)Included in Other current liabilities ($561 million) and Other noncurrent liabilities ($156 million).

Note 4. Other (Income)/Deductions Net

Components of Other (income)/deductions net include:

Three Months Ended

(MILLIONS)April 4,

2021March 29,

2020

Interest income$ $(34)

Interest expense336 390

Net interest expense

336 356

Royalty-related income(176)(119)

Net (gains)/losses on asset disposals(39)1

Net (gains)/losses recognized during the period on equity securities(a)

(401)255

Income from collaborations, out-licensing arrangements and sales of compound/product rights(b)

(231)(115)

Net periodic benefit costs/(credits) other than service costs(c)

(266)(103)

Certain legal matters, net51 9

Consumer Healthcare JV equity method (income)/loss(d)

(62)33

Other, net(216)(126)

Other (income)/deductions net$(1,004)$190

(a)The gains in the first quarter of 2021 include, among other things, unrealized gains of $409 million related to investments in Allogene and BioNTech. The losses in the first quarter of 2020 include, among other things, unrealized losses of $134 million related to our investment in Allogene.

(b)The first quarter of 2021 includes, among other things, $188 million of net collaboration income from BioNTech related to the COVID-19 vaccine. The first quarter of 2020 mainly includes, among other things, an upfront payment to us of $75 million from our sale of our CK1 assets to Biogen, Inc.

(c)Amounts include the impact of a change in accounting principle. See Notes 1C and 10.

(d)See Note 2B.

Note 5. Tax Matters

A. Taxes on Income from Continuing Operations

Our effective tax rate for continuing operations was 14.2% for the first quarter of 2021, compared to 12.6% for the first quarter of 2020. The higher effective tax rate was primarily due to an unfavorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.

We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings over eight years through 2026. The third annual installment of this liability was paid by its April 15, 2021 due date and is reported in current Income taxes payable as of April 4, 2021. The remaining liability is reported in noncurrent Other taxes payable. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.

B. Tax Contingencies

We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.

The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. With respect to Pfizer, the IRS has issued Revenue Agent s Reports (RARs) for tax years 2011-2013 and 2014-2015. We are not in agreement with the RARs and are currently appealing certain disputed issues. Tax years 2016-2018 are currently under audit. Tax years 2019-2021 are open

15

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

but not under audit. All other tax years are closed. In addition to the open audit years in the U.S., we have open audit years in certain major international tax jurisdictions dating back to 2010.

For additional information, see Note 5D in our 2020 Form 10-K.

C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)

Components of Tax provision/(benefit) on other comprehensive income/(loss) include:

Three Months Ended

(MILLIONS)April 4,

2021March 29,

2020

Foreign currency translation adjustments, net(a)

$21 $(247)

Unrealized holding gains/(losses) on derivative financial instruments, net59 (133)

Reclassification adjustments for (gains)/losses included in net income34 15

93 (118)

Unrealized holding gains/(losses) on available-for-sale securities, net10 (6)

Reclassification adjustments for (gains)/losses included in net income(30)2

(20)(5)

Reclassification adjustments related to amortization of prior service costs and other, net

(10)(11)

Other

(10)(11)

Tax provision/(benefit) on other comprehensive income/(loss)$84 $(380)

(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that we intend to hold indefinitely.

Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests

The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:

Net Unrealized Gains/(Losses)Benefit Plans

(MILLIONS)Foreign Currency Translation Adjustments Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)

Balance, December 31, 2020(a)

$(5,450)$(428)$116 $452 $(5,310)

Other comprehensive income/(loss)(b)

442 380 (142)(33)646

Balance, April 4, 2021$(5,008)$(48)$(26)$419 $(4,664)

(a)Amounts include the impact of a change in accounting principle. See Note 1C.

(b)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests. Foreign currency translation adjustments primarily include gains from the strengthening of the U.K. pound, euro and Australian dollar against the U.S. dollar, and net gains related to the impact of our net investment hedging program, partially offset by net losses from foreign currency translation adjustments related to our equity-method investment in the Consumer Healthcare JV (see Note 2B).

16

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 7. Financial Instruments

A. Fair Value Measurements

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy, using a Market Approach:

April 4, 2021December 31, 2020

(MILLIONS)TotalLevel 1Level 2TotalLevel 1Level 2

Financial assets:

Short-term investments

Classified as equity securities with readily determinable fair values:

Money market funds$1,427 $ $1,427 $567 $ $567

Classified as available-for-sale debt securities:

Government and agency non-U.S.

6,169 6,169 7,719 7,719

Government and agency U.S.

1,221 1,221 982 982

Corporate and other

902 902 1,008 1,008

8,292 8,292 9,709 9,709

Total short-term investments9,719 9,719 10,276 10,276

Other current assets

Derivative assets:

Interest rate contracts

5 5 18 18

Foreign exchange contracts

389 389 234 234

Total other current assets394 394 251 251

Long-term investments

Classified as equity securities with readily determinable fair values(a)

3,123 3,046 77 2,809 2,776 32

Classified as available-for-sale debt securities:

Government and agency non-U.S.

9 9 6 6

Government and agency U.S.

66 66 121 121

Corporate and other

75 75 128 128

Total long-term investments3,198 3,046 152 2,936 2,776 160

Other noncurrent assets

Derivative assets:

Interest rate contracts

21 21 117 117

Foreign exchange contracts

106 106 5 5

Total derivative assets127 127 122 122

Insurance contracts(b)

726 726 693 693

Total other noncurrent assets853 853 814 814

Total assets$14,165 $3,046 $11,119 $14,278 $2,776 $11,501

Financial liabilities:

Other current liabilities

Derivative liabilities:

Foreign exchange contracts

$239 $ $239 $501 $ $501

Total other current liabilities239 239 501 501

Other noncurrent liabilities

Derivative liabilities:

Foreign exchange contracts

494 494 599 599

Total other noncurrent liabilities494 494 599 599

Total liabilities$732 $ $732 $1,100 $ $1,100

(a)Long-term equity securities of $168 million as of April 4, 2021 and $190 million as of December 31, 2020 were held in restricted trusts for employee benefit plans.

(b)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions net (see Note 4).

17

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis

Carrying values and estimated fair values using a market approach:

April 4, 2021December 31, 2020

(MILLIONS)Carrying ValueEstimated Fair Value at Level 2Carrying ValueEstimated Fair Value at Level 2

Financial Liabilities

Long-term debt, excluding the current portion$35,347 $40,504 $37,133 $45,533

The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of April 4, 2021 and December 31, 2020. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.

B. Investments

Total Short-Term, Long-Term and Equity-Method Investments

The following summarizes our investments by classification type:

(MILLIONS)April 4, 2021December 31, 2020

Short-term investments

Equity securities with readily determinable fair values(a)

$1,427 $567

Available-for-sale debt securities8,292 9,709

Held-to-maturity debt securities2,180 161

Total Short-term investments$11,899 $10,437

Long-term investments

Equity securities with readily determinable fair values$3,123 $2,809

Available-for-sale debt securities75 128

Held-to-maturity debt securities31 37

Private equity securities at cost(b)

467 432

Total Long-term investments$3,696 $3,406

Equity-method investments16,532 16,856

Total long-term investments and equity-method investments$20,228 $20,262

Held-to-maturity cash equivalents$60 $89

(a)As of April 4, 2021 and December 31, 2020, includes money market funds primarily invested in U.S. Treasury and government debt.

(b)Represent investments in the life sciences sector.

Debt Securities

At April 4, 2021, our debt investment portfolio consisted of debt securities issued across diverse governments, corporate and financial institutions, which are investment-grade. The contractual or estimated maturities, are as follows:

April 4, 2021December 31, 2020

Gross UnrealizedMaturities (in Years)Gross Unrealized

(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1

to 5Over 5Amortized CostGainsLossesFair Value

Available-for-sale debt securities

Government and agency non-U.S.

$6,209 $23 $(54)$6,178 $6,169 $9 $ $7,593 $136 $(4)$7,725

Government and agency U.S.

1,288 (1)1,287 1,221 66 1,104 (1)1,103

Corporate and other900 3 903 902 1,006 2 1,008

Held-to-maturity debt securities

Time deposits and other

423 423 397 16 10 283 283

Government and agency non-U.S.

1,847 1,847 1,842 4 1 5 5

Total debt securities$10,667 $25 $(55)$10,637 $10,531 $94 $11 $9,991 $138 $(5)$10,124

Any expected credit losses to these portfolios would be immaterial to our financial statements.

18

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Equity Securities

The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:

Three Months Ended

(MILLIONS)April 4,

2021March 29,

2020

Net (gains)/losses recognized during the period on equity securities(a)

$(401)$255

Less: Net (gains)/losses recognized during the period on equity securities sold during the period(28)(19)

Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date(b)

$(372)$274

(a)Reported in Other (income)/deductions net. See Note 4.

(b)Included in net unrealized gains are observable price changes on equity securities without readily determinable fair values. Since January 1, 2018, there were cumulative impairments and downward adjustments of $87 million and upward adjustments of $61 million. Impairments, downward and upward adjustments were not significant in the first quarters of 2021 and 2020.

C. Short-Term Borrowings

Short-term borrowings include:

(MILLIONS)April 4,

2021December 31, 2020

Commercial paper$416 $556

Current portion of long-term debt, principal amount3,679 2,004

Other short-term borrowings, principal amount(a)

260 145

Total short-term borrowings, principal amount

4,355 2,705

Net fair value adjustments related to hedging and purchase accounting

Net unamortized discounts, premiums and debt issuance costs(3)(2)

Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted

$4,352 $2,703

(a)Includes cash collateral. See Note 7F.

D. Long-Term Debt

The following summarizes the aggregate principal amount of our senior unsecured long-term debt, and adjustments to report our aggregate long-term debt:

(MILLIONS)April 4,

2021December 31, 2020

Total long-term debt, principal amount$34,032 $35,774